Skip to main content
Erschienen in: Tumor Biology 6/2011

01.12.2011 | Research Article

Nanoparticle-delivered VEGF-silencing cassette and suicide gene expression cassettes inhibit colon carcinoma growth in vitro and in vivo

verfasst von: Aimin Leng, Jing Yang, Ting Liu, Jianfang Cui, Xiu-hua Li, Yanan Zhu, Ting Xiong, Yuxiang Chen

Erschienen in: Tumor Biology | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

The strategies for tumor-specific expression of suicide genes and target tumor angiogenesis have been tested in tumors. However, the anti-tumor efficacy of the combination of these two strategies, particularly, delivering suicide gene and anti-angiogenesis agent by nanoparticles, has not yet been evaluated in colon carcinoma. We constructed a cassette to silence VEGF-A expression and express a fused yCDglyTK gene driven by tumor-specific promoter (shVEGF-CDTK). The DNA carrying shVEGF-CDTK was delivered into colon carcinoma cells by calcium phosphate nanoparticles (CPNPs). Cell proliferation was measured by MTT assay, and apoptosis was detected by flow cytometry. The anti-tumor effect of the combined cassette was tested in xenograft animal model. With 5-fluorocytosine (5-FC), CPNP-delivered shVEGF-CDTK DNA (CPNP-shVEGF-CDTK) showed high expression of fused yCDglyTK gene and effectively silenced VEGF-A expression in vitro and in vivo, which significantly inhibited colon carcinoma cell proliferation and induced apoptosis in vitro. With 5-FC, the systemic delivery of CPNP-shVEGF-CDTK significantly inhibited tumor growth in the colon carcinoma xenograft animal model. The combined cassette is obviously effective in inhibiting tumor cell proliferation and inducing apoptosis in vitro and tumor growth in vivo than the CPNP-shVEGF or CPNP-CDTK alone. The combination of VEGF-A-silencing and tumor-specific expression of suicide gene is an effective strategy for colon carcinoma treatment.
Literatur
1.
Zurück zum Zitat Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.PubMedCrossRef Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.PubMedCrossRef
2.
Zurück zum Zitat Xu AG, Yu ZJ, Jiang B, et al. Colorectal cancer in Guangdong Province of China: a demographic and anatomic survey. World J Gastroenterol. 2010;16:960–5.PubMedCrossRef Xu AG, Yu ZJ, Jiang B, et al. Colorectal cancer in Guangdong Province of China: a demographic and anatomic survey. World J Gastroenterol. 2010;16:960–5.PubMedCrossRef
3.
Zurück zum Zitat Ades S. Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to practice. Oncology. 2009;23:162–7.PubMed Ades S. Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to practice. Oncology. 2009;23:162–7.PubMed
4.
Zurück zum Zitat Blagbrough IS, Zara C. Animal models for target diseases in gene therapy—using DNA and siRNA delivery strategies. Pharm Res. 2009;26:1–18.PubMedCrossRef Blagbrough IS, Zara C. Animal models for target diseases in gene therapy—using DNA and siRNA delivery strategies. Pharm Res. 2009;26:1–18.PubMedCrossRef
5.
Zurück zum Zitat Collins SA, Guinn BA, Harrison PT, et al. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther. 2008;8:66–78.PubMedCrossRef Collins SA, Guinn BA, Harrison PT, et al. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther. 2008;8:66–78.PubMedCrossRef
6.
Zurück zum Zitat Karmali PP, Chaudhuri A. Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises. Med Res Rev. 2007;27:696–722.PubMedCrossRef Karmali PP, Chaudhuri A. Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises. Med Res Rev. 2007;27:696–722.PubMedCrossRef
7.
Zurück zum Zitat Kodama K, Katayama Y, Shoji Y, et al. The features and shortcomings for gene delivery of current non-viral carriers. Curr Med Chem. 2006;13:2155–61.PubMedCrossRef Kodama K, Katayama Y, Shoji Y, et al. The features and shortcomings for gene delivery of current non-viral carriers. Curr Med Chem. 2006;13:2155–61.PubMedCrossRef
8.
Zurück zum Zitat Hart SL. Multifunctional nanocomplexes for gene transfer and gene therapy. Cell Biol Toxicol. 2010;26:69–81.PubMedCrossRef Hart SL. Multifunctional nanocomplexes for gene transfer and gene therapy. Cell Biol Toxicol. 2010;26:69–81.PubMedCrossRef
9.
10.
Zurück zum Zitat Liu T, Tang A, Zhang G, et al. Calcium phosphate nanoparticles as a novel nonviral vector for efficient transfection of DNA in cancer gene therapy. Cancer Biother Radiopharm. 2005;20:141–9.PubMedCrossRef Liu T, Tang A, Zhang G, et al. Calcium phosphate nanoparticles as a novel nonviral vector for efficient transfection of DNA in cancer gene therapy. Cancer Biother Radiopharm. 2005;20:141–9.PubMedCrossRef
11.
Zurück zum Zitat Khurana B, Goyal AK, Budhiraja A, et al. siRNA delivery using nanocarriers—an efficient tool for gene silencing. Curr Gene Ther. 2010;10:139–55.PubMedCrossRef Khurana B, Goyal AK, Budhiraja A, et al. siRNA delivery using nanocarriers—an efficient tool for gene silencing. Curr Gene Ther. 2010;10:139–55.PubMedCrossRef
12.
Zurück zum Zitat Agrawal N, Dasaradhi PV, Mohmmed A, et al. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 2003;67:657–85.PubMedCrossRef Agrawal N, Dasaradhi PV, Mohmmed A, et al. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 2003;67:657–85.PubMedCrossRef
13.
Zurück zum Zitat Shinkaruk S, Bayle M, Laïn G, et al. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents. 2003;3:95–117.PubMedCrossRef Shinkaruk S, Bayle M, Laïn G, et al. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents. 2003;3:95–117.PubMedCrossRef
14.
Zurück zum Zitat Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer. 2008;8:579–91.PubMedCrossRef Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer. 2008;8:579–91.PubMedCrossRef
15.
Zurück zum Zitat Yang Y, Bai Y, Xie G, et al. Efficient inhibition of non-small-cell lung cancer xenograft by systemic delivery of plasmid-encoding short-hairpin RNA targeting VEGF. Cancer Biother Radiopharm. 2010;25:65–73.PubMedCrossRef Yang Y, Bai Y, Xie G, et al. Efficient inhibition of non-small-cell lung cancer xenograft by systemic delivery of plasmid-encoding short-hairpin RNA targeting VEGF. Cancer Biother Radiopharm. 2010;25:65–73.PubMedCrossRef
16.
Zurück zum Zitat Zhang G, Liu T, Chen YH, et al. Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo. Clin Cancer Res. 2009;15:201–7.PubMedCrossRef Zhang G, Liu T, Chen YH, et al. Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo. Clin Cancer Res. 2009;15:201–7.PubMedCrossRef
17.
Zurück zum Zitat Xia K, Liang D, Tang A, et al. A novel fusion suicide gene yeast CDglyTK plays a role in radio-gene therapy of nasopharyngeal carcinoma. Cancer Gene Ther. 2004;11:790–6.PubMedCrossRef Xia K, Liang D, Tang A, et al. A novel fusion suicide gene yeast CDglyTK plays a role in radio-gene therapy of nasopharyngeal carcinoma. Cancer Gene Ther. 2004;11:790–6.PubMedCrossRef
18.
Zurück zum Zitat Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005;23:338–51.PubMed Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005;23:338–51.PubMed
19.
Zurück zum Zitat Liu T, Zhang G, Chen YH, et al. Tissue specific expression of suicide genes delivered by nanoparticles inhibits gastric carcinoma growth. Cancer Biol Ther. 2006;5:1683–90.PubMed Liu T, Zhang G, Chen YH, et al. Tissue specific expression of suicide genes delivered by nanoparticles inhibits gastric carcinoma growth. Cancer Biol Ther. 2006;5:1683–90.PubMed
20.
Zurück zum Zitat Liu T, Tang A, Zhang G, Chen Y, Zhang J, Peng S, et al. Calcium phosphate nanoparticles as a novel nonviral vector for efficient transfection of DNA in cancer gene therapy. Cancer Biother Radiopharm. 2005;20:141–9.PubMedCrossRef Liu T, Tang A, Zhang G, Chen Y, Zhang J, Peng S, et al. Calcium phosphate nanoparticles as a novel nonviral vector for efficient transfection of DNA in cancer gene therapy. Cancer Biother Radiopharm. 2005;20:141–9.PubMedCrossRef
21.
Zurück zum Zitat Zhang X, Kon T, Wang H, et al. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res. 2004;64:8139–42.PubMedCrossRef Zhang X, Kon T, Wang H, et al. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res. 2004;64:8139–42.PubMedCrossRef
22.
Zurück zum Zitat Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401–10.PubMedCrossRef Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401–10.PubMedCrossRef
23.
Zurück zum Zitat Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs. 2009;23:289–304.PubMedCrossRef Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs. 2009;23:289–304.PubMedCrossRef
24.
Zurück zum Zitat Takahashi Y, Nishikawa M, Takakura Y. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Adv Drug Deliv Rev. 2009;61:760–6.PubMedCrossRef Takahashi Y, Nishikawa M, Takakura Y. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Adv Drug Deliv Rev. 2009;61:760–6.PubMedCrossRef
25.
Zurück zum Zitat Maitra A. Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy. Expert Rev Mol Diagn. 2005;5:893–905.PubMedCrossRef Maitra A. Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy. Expert Rev Mol Diagn. 2005;5:893–905.PubMedCrossRef
Metadaten
Titel
Nanoparticle-delivered VEGF-silencing cassette and suicide gene expression cassettes inhibit colon carcinoma growth in vitro and in vivo
verfasst von
Aimin Leng
Jing Yang
Ting Liu
Jianfang Cui
Xiu-hua Li
Yanan Zhu
Ting Xiong
Yuxiang Chen
Publikationsdatum
01.12.2011
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2011
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0210-5

Weitere Artikel der Ausgabe 6/2011

Tumor Biology 6/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.